DataMeds AI, Inc MEDS
- Market cap
- $10.9M
- P/E
- 0.0×
Follow MEDS
Target Price Range
Analyst price targets
Free account| 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| — | — | — | — | — | — | — | — | — | 16.80 |
Analyst estimates 2026–2028 Powerpack |
Low Price
|
||
| — | — | — | — | — | — | — | — | — | 352.00 |
High Price
|
|||
| — | — | — | — | — | — | — | 31 | 31 | 7 |
Employees
|
|||
| — | — | — | — | — | — | — | 0 | 1 | 3 |
Revenue/Emp
|
|||
| — | — | — | — | — | — | — | — | 18 | 23 |
Revenue
|
|||
| — | — | — | — | — | — | — | — | 9.75% | (27.54%) |
Gross Margin
|
|||
| — | — | — | — | — | — | — | (3) | (7) | (101) |
EBT
|
|||
| — | — | — | — | — | — | — | 0.00% | (37.82%) | (433.95%) |
EBT Margin
|
|||
| — | — | — | — | — | — | — | (3) | (7) | (101) |
Net Income
|
|||
| — | — | — | — | — | — | — | — | 1 | 16 |
Depreciation
|
|||
| — | — | — | — | — | — | — | 0.00 | 19.18 | 16.44 |
Revenue/Sh
|
|||
| — | — | — | — | — | — | — | (3.24) | (7.50) | (71.50) |
Earnings/Sh
|
|||
| — | — | — | — | — | — | — | (0.39) | (1.30) | (7.65) |
Cash Flow/Sh
|
|||
| — | — | — | — | — | — | — | 0.00 | (0.40) | (0.62) |
Capex/Sh
|
|||
| — | — | — | — | — | — | — | (0.39) | (1.70) | (8.27) |
Free CF/Sh
|
|||
| — | — | — | — | — | — | — | (3.24) | 7.13 | (8.77) |
Book Value/Sh
|
|||
| — | — | — | — | — | — | — | 1 | 1 | 1 |
Shares
|
|||
| — | — | — | — | — | — | — | — | 0.00 | 0.00 |
PE Ratio
|
|||
| — | — | — | — | — | — | — | — | 0.00 | 1.22 |
PS Ratio
|
|||
| — | — | — | — | — | — | — | — | 26.73 | 0.00 |
PB Ratio
|
|||
| — | — | — | — | — | — | — | — | 0.00 | 2.22 |
EV/Sales
|
|||
| — | — | — | — | — | — | — | — | (165.21) | (4.42) |
EV/FCF
|
|||
| — | — | — | — | — | — | — | 0 | (1) | (11) |
Op' Cash Flow
|
|||
| — | — | — | — | — | — | — | — | 0 | (1) |
Capex
|
|||
| — | — | — | — | — | — | — | 0 | (2) | (12) |
FCF
|
|||
| — | — | — | — | — | — | — | (3) | (23) | (27) |
Working Cap'
|
|||
| — | — | — | — | — | — | — | 0 | 23 | 23 |
Total Debt
|
|||
| — | — | — | — | — | — | — | 0 | 22 | 23 |
Net Debt
|
|||
| — | — | — | — | — | — | — | (3) | 7 | (12) |
Sh' Equity
|
|||
| — | — | — | — | — | — | — | 0.00% | (23.78%) | (230.71%) |
ROA
|
|||
| — | — | — | — | — | — | — | 0.00% | (13.20%) | (532.81%) |
ROIC
|
|||
| — | — | — | — | — | — | — | 0.00% | (357.65%) | 3,545.16% |
ROE
|
|||
DataMeds AI, Inc peers in Pharmaceutical Retailers
| Company | Market cap | P/E | Compare |
|---|---|---|---|
| SCNX Scienture Holdings, Inc. | $12.3M | 0.0× | Compare |
| POM Pomdoctor Limited - Sponsored ADR | $7.8M | — | Compare |
| PETS PetMed Express, Inc. | $33.7M | 0.0× | Compare |
| RDGT Ridgetech Inc. | $3.3M | 0.0× | Compare |
| Company | Market cap | P/E | Compare |
|---|---|---|---|
| MDVLQ MedAvail Holdings, Inc. | $2.9M | 0.0× | Compare |
| HITI High Tide Inc. | $240.2M | 0.0× | Compare |
| BIMI BIMI Holdings Inc. | $170.0K | 0.0× | Compare |
DataMeds AI, Inc (MEDS) key facts
- DataMeds AI, Inc (MEDS) is a Pharmaceutical Retailers company in the Healthcare sector, listed on Nasdaq.
- DataMeds AI, Inc’s revenue for fiscal 2025 (year ended December 2025) was $23.3 million, up 28.7% from fiscal 2024.
- As of September 25, 2026, MEDS traded at $3.11, a market capitalization of $10.9 million.
- Return on equity was 3,545.2% and debt-to-equity -1.01.
DataMeds AI, Inc (MEDS) Latest News
25 Sep
DataMeds AI, Inc. (MEDS) says Interim Co-CEO Gerald Commissiong will present 'What Patients Really Want' at the National Telehealth and Virtual Care Summit in Las Vegas on Sept. 28, 2026, at 9:15 a.m. PT. He will discuss the growing desire of patients to own their health data and how the company is expanding access to telehealth and pharmaceutical services through its 'Health Lives Here' campaign and the Health Lives Here mobile app developed with NFL Alumni Health. DataMeds emphasizes helping patients access, manage and monetize data while reducing provider data-access frustrations, and highlights its integration of Health IT platforms with EinsteinRx AI, the PharmacyChain smart-contracts platform, Corexa Health dispensing services, and products from Tollo Health. The summit focuses on strategies to improve care, analytics, and accessibility in digital health and virtual care. It signals strategic emphasis on patient-owned data and telehealth expansion, but lacks immediate financial milestones or results.
18 Sep
DataMeds AI Inc's acquisition lacks bullish potential for MEDS stock. Acquisition offers limited strategic upside and fails to shift MEDS trajectory or investor outlook materially.
16 Sep
DataMEDS AI acquires Helomics for $1.5 million, expanding operations into cancer diagnostics. Helomics acquisition marks major strategic expansion into cancer diagnostics with potential to alter company trajectory.
15 Sep
DataMeds AI acquires Helomics AI Cancer Diagnostics Lab and Precision Oncology CRO businesses from Axe Compute. Acquisition adds cancer diagnostics lab and oncology CRO operations to DataMeds AI core business.
Axe Compute sold its Helomics AI Cancer Diagnostics Lab Business to DataMeds AI, Inc., finalizing Axe Compute's transition to a Neocloud GPU-as-a-Service platform. Acquisition of Helomics gives DataMeds a cancer diagnostics lab business with potential to expand AI healthcare operations and alter growth trajectory.
8 Sep
DataMeds AI Inc and Tollo Health partnered with the NFL Alumni Association to launch the Health Lives Here national campaign rollout. Partnership with NFL Alumni Association delivers moderate visibility boost in health initiatives without altering core operations.
17 Aug
DataMeds AI, Inc (MEDS) reported second quarter 2026 financial results and issued a business update. Quarterly financial results and business updates typically affect near-term investor views and operational outlook without guaranteeing major trajectory shifts.
31 Jul
DataMeds AI Inc's Corexa Pharmacy launches Tollo Health's Tollovid(R) and Galactovid(TM) products. Pharmacy subsidiary product launch adds operational activity with limited scope for major trajectory shifts.
26 Jun
Wellgistics Health, Inc. (WGRX) selects DataMeds AI, Inc. as proposed new name. Name rebrand to DataMeds AI signals AI-focused pivot that may moderately lift investor sentiment and positioning.
1 Jun
Wellgistics Health, Inc. releases mid-year 2026 corporate outlook. Corporate outlook provides forward guidance that can shift investor sentiment and near-term stock performance.
27 May
Wellgistics Health refinances outstanding convertible debt and raises $6.5M. Debt refinancing plus modest capital raise improves liquidity without shifting core operations or long-term trajectory.
20 May
Wellgistics Health, Inc. (WGRX) and Datavault AI have agreed to form DelivMeds AI. Formation of DelivMeds AI marks a major strategic move that can significantly boost Wellgistics Health's AI capabilities and market trajectory.
19 May
Wellgistics Health, Inc. released first quarter 2026 financial results and a business update. Quarterly financials and business updates deliver performance data that can shift near-term investor views and valuation.
14 May
Wellgistics Health, Inc. (WGRX) accelerates digital health expansion of its RPM, RTM, and CCM pilot programs via planned acquisition of WellCare Today and its proprietary Samsung Galaxy Watch Care Monitoring Program. Planned acquisition integrates proprietary Samsung monitoring tech to boost WGRX's remote patient and chronic care offerings, driving strategic growth in digital health.
13 May
Wellgistics Health, Inc. (WGRX) announced a pilot MSO collaboration with Kare PharmTech targeting the $14 billion U.S. market for Chronic Care Management (CCM) and Remote Patient Monitoring (RPM) services. Pilot MSO collaboration targets $14 billion CCM/RPM market, enabling major strategic entry into high-growth telehealth sectors.
14 Apr
Wellgistics Health, Inc. (WGRX) and Kare PharmTech have executed a joint venture to expand access to over 200,000 patient lives. Joint venture expands patient access by over 200,000 lives, enabling major strategic growth in market reach and revenue potential for WGRX.
2 Apr
Wellgistics Health, Inc. (WGRX) is exploring a $105 million acquisition of Neuritek to expand its healthcare platform. A $105M acquisition of Neuritek constitutes a major strategic move to enhance WGRX's healthcare platform and competitive positioning.
25 Mar
Thunder Rock Capital served as exclusive M&A advisor to Neuritek Therapeutics, Inc. on its proposed $105,000,000 acquisition by Wellgistics Health, Inc. (WGRX). Proposed $105 million acquisition fundamentally transforms Wellgistics Health's scale, capabilities, and long-term prospects.
23 Mar
Wellgistics Health Inc. (WGRX) signed a $105,000,000 letter of intent to evaluate acquiring Neuritek Therapeutics, Inc., a pioneer in innovative therapies for neurological and psychiatric disorders. A $105 million LOI for acquiring an innovative neuro-psych therapeutics company represents a major strategic expansion with high potential to transform WGRX's growth trajectory and market position.
13 Mar
Wellgistics Health, Inc. (WGRX) president releases letter to shareholders outlining emerging patient care-centric strategic direction. President's letter signals major strategic shift to patient care-centric focus, poised to significantly alter company trajectory and investor sentiment.
11 Mar
Wellgistics Health, Inc. (WGRX) bolsters its PharmacyChain platform by integrating insurance eligibility and benefits verification capabilities to streamline pharmacy operations. Adding insurance verification to PharmacyChain enhances operational efficiency and competitive positioning in pharmacy services without fundamentally transforming the business.
9 Mar
Wellgistics Health, Inc. (WGRX) launches Forzet(TM) to address muscle loss from Ozempic and GLP-1 drugs, targeting a $70 billion market breakthrough. Forzet(TM) targets $70B market for GLP-1 muscle loss side effects, representing major product launch with potential to alter WGRX trajectory.
5 Mar
Wellgistics Health (WGRX) selects top five blockchain platforms to launch patent-protected PharmacyChain(TM), a smart contracts-enabled system for pharmaceutical drug tracking to comply with industry-wide serialization mandates. Initiating a patent-protected blockchain drug tracking system aligns WGRX with critical serialization mandates, enabling major strategic positioning in pharma supply chain tech.
25 Feb
Datavault AI (DVLT) and Wellgistics Health (WGRX) expand partnership to launch blockchain-powered Health-as-a-Service (HaaS) model. Partnership expansion launches innovative blockchain-powered HaaS model, marking a major strategic advancement for WGRX's health tech offerings.
23 Feb
DataVault AI and Wellgistics Health, Inc. (WGRX) announce plans to expand their partnership by incorporating healthcare delivery intellectual property into Healthcare as a Service (HaaS) via blockchain-enabled smart contracts. Partnership expansion into blockchain-enabled HaaS integrates advanced IP, positioning WGRX for major strategic growth in healthcare innovation and market dynamics.
11 Feb
Wellgistics Health, Inc. (WGRX) is expanding its partnership with Tollo Health to incorporate telehealth and mental health AI capabilities. This strategic move aims to enhance Wellgistics' service offerings and improve patient care through advanced technology. The partnership is expected to position Wellgistics favorably in the growing telehealth market, addressing increasing demand for mental health services. The partnership expansion is likely to significantly enhance Wellgistics' service capabilities and competitive positioning in the telehealth sector.
9 Feb
NFL Alumni Health has partnered with Wellgistics Health, Inc. (WGRX) to implement technology aimed at enhancing health outcomes for former NFL players and rural communities. This collaboration seeks to leverage innovative solutions to address health challenges faced by these populations, potentially improving access to healthcare and overall well-being. The partnership represents a significant strategic move that could enhance Wellgistics Health's market position and investor sentiment.
8 Jan
Wellgistics Health, Inc. (WGRX) has outlined its corporate outlook for 2026, highlighting strategic initiatives aimed at enhancing operational efficiency and expanding market presence. The company anticipates significant growth driven by innovative product offerings and an increased focus on customer engagement. Key performance indicators suggest a positive trajectory, with projections indicating improved financial metrics and market share expansion in the coming years. The outlined strategic initiatives and growth projections are expected to significantly impact the company's future performance and market positioning.
7 Jan
Wellgistics Health, Inc. (WGRX) has provided its corporate outlook for 2026, outlining strategic initiatives aimed at enhancing operational efficiency and expanding market presence. The company anticipates significant growth driven by innovative product offerings and improved service delivery. Key focus areas include technology integration and partnerships to bolster competitive positioning in the healthcare sector. Financial projections indicate a positive trajectory, with expectations for increased revenue and market share over the next few years. The outlined strategic initiatives and growth projections are likely to significantly impact the company's future performance and market positioning.
8 Dec
Wellgistics Health, Inc. (WGRX) has announced the launch of its diabetes drug, Brenzavvy(R), which will be available through the Wellgistics Pharmacy Network. This launch aims to enhance the company's product offerings in the diabetes treatment market and expand its reach within the healthcare sector. The launch of Brenzavvy(R) represents a significant strategic move that could enhance Wellgistics' competitive positioning and market presence in the diabetes treatment sector.